MG
Maher Gandhi
Translational Research Institute, Mater Research, UQ, Royal Australasian College of Physicians, University of Cambridge, Royal College of Pathologists
Research areas: Medicine · Pathology and Forensic Medicine · Lymphoma Diagnosis and Treatment · Viral-associated cancers and disorders · Chronic Lymphocytic Leukemia Research
0000-0003-1000-5393
Employment
-
Translational Research Institute Chief Executive Officer2025 - Present
-
Mater Research, UQ Group Leader
Education
- 2005 - Present
- 2003 - Present
-
Royal College of Pathologists FRCPath2002 - Present
-
Royal College of Physicians UK FRCP1994 - Present
-
University of Aberdeen MBChB1989 - Present
Projects & Funding
Projects & funding information is unavailable.
Publications (255)
- SIGN of the times: DC-SIGN and the follicular lymphoma niche Save
- Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy Save
- FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma Save
- T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial Save
- EBNA2: a viral maestra conducting a symphony orchestra Save
- Epstein–Barr virus‐associated lymphomas decoded Save
- EBV-infected hematopoietic stem cells drive CAEBV Save
- A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma Save
- Genetic susceptibility to EBV-related disease Save
- The PO4-tential for Less Toxic CAR T-cell Therapies Save
- Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Save
- Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. Save
- CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma. Save
- Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders. Save
- Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma Save
- Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. Save
- Discordant solutions to discordant problems Save
- EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity Save
- Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience Save
- Targeted Treatment of Follicular Lymphoma. Save